PDE inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S1512 Tadalafil Tadalafil is a PDE-5 inhibitor with IC50 of 1.8 nM in a cell-free assay. This compound is at least 9000 times more selective for PDE5 than most of the other families of PDEs, with the exception of PDE11. It can partial inhibits PDE11
J Immunother Cancer, 2024, 12(11)e009805
Cell Mol Life Sci, 2024, 81(1):434
J Clin Invest, 2021, 131(1)136779
Verified customer review of Tadalafil
S1895 Dipyridamole Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.
Nature, 2025, 10.1038/s41586-025-09755-9
Theranostics, 2024, 14(18):6947-6968
J Immunother Cancer, 2024, 12(11)e009805
S7858 Dibutyryl cAMP (db cAMP/Bucladesine) sodium Bucladesine sodium is a cell-permeable PKA activator by mimicing the action of endogenous cAMP. Dibutyryl-cAMP (Bucladesine) is also a phosphodiesterase (PDE) inhibitor.
Cell, 2025, S0092-8674(25)00735-4
Nat Neurosci, 2025, 28(6):1174-1184
Nat Commun, 2025, 16(1):6151
S1431 Sildenafil Citrate Sildenafil Citrate, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective treatment for erectile dysfunction.
Br J Pharmacol, 2025, 10.1111/bph.70166
Drug Des Devel Ther, 2025, 19:6487-6504
J Pharm Pharmacol, 2023, rgad045
Verified customer review of Sildenafil Citrate
S4684 Sildenafil Sildenafil (Revatio, UK-92480, Viagra) is a Phosphodiesterase 5 Inhibitor with IC50 of 5.22 nM.
Adv Sci (Weinh), 2024, 11(40):e2407712
J Immunother Cancer, 2024, 12(11)e009805
Brain, 2023, 146(6):2453-2463
Verified customer review of Sildenafil
S2131 Roflumilast Roflumilast is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM in a cell-free assay.
Redox Biol, 2025, 81:103563
Invest Ophthalmol Vis Sci, 2024, 65(12):38
Respir Investig, 2024, 62(3):455-461
Verified customer review of Roflumilast
S1430 Rolipram The PDE4 selective inhibitor, Rolipram, inhibited immunopurified PDE4B and PDE4D activities similarly, with IC50 values of approx. 130 nM and 240 nM respectively; an anti-inflammatory agent.
Elife, 2022, 11e73511
ProQuest, 2022, 30509631
Acta Pharmacol Sin, 2021, 10.1038/s41401-021-00768-4
Verified customer review of Rolipram
S5836 IBMX (3-Isobutyl-1-methylxanthine) IBMX (Isobutylmethylxanthine, 1-Methyl-3-Isobutylxanthine) is a nonspecific inhibitor of phosphodiesterase (PDE) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. It may enhance the intracellular cAMP levels and also acts as an adenosine (A1) receptor antagonist.
J Biomed Sci, 2025, 32(1):31
J Hematol Oncol, 2023, 16(1):30
J Hematol Oncol, 2023, 16(1):30
S2515 Vardenafil HCl Trihydrate Vardenafil HCl Trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
Gastroenterology, 2020, 159(3):1068-1084.e2
Bone, 2020, 10.1016/j.bone.2020.115305
Pulm Pharmacol Ther, 2020, 66:101985
Verified customer review of Vardenafil HCl Trihydrate
S8034 Apremilast Apremilast (CC-10004) is a potent and orally active PDE4 and TNF-α inhibitor with IC50 of 74 nM and 77 nM, respectively.
Signal Transduct Target Ther, 2023, 8(1):40
Acta Pharm Sin B, 2022, 12(1):228-245
Int J Mol Sci, 2021, 22(23)12878

Signaling Pathway Map